Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
- PMID: 32521716
- PMCID: PMC7311973
- DOI: 10.3390/ijms21114091
Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies due to the rapid rate of metastasis and high resistance to currently applied cancer therapies. The complex mechanism underlying the development and progression of PDAC includes interactions between genomic, epigenomic, and signaling pathway alterations. In this review, we summarize the current research findings on the deregulation of epigenetic mechanisms in PDAC and the influence of the epigenome on the dynamics of the gene expression changes underlying epithelial-mesenchymal transition (EMT), which is responsible for the invasive phenotype of cancer cells and, therefore, their metastatic potential. More importantly, we provide an overview of the studies that uncover potentially actionable pathways. These studies provide a scientific basis to test epigenetic drug efficacy in synergy with other anticancer therapies in future clinical trials, in order to reverse acquired therapy resistance. Thus, epigenomics has the potential to generate relevant new knowledge of both a biological and clinical impact. Moreover, the potential, hurdles, and challenges of predictive biomarker discoveries will be discussed, with a special focus on the promise of liquid biopsies.
Keywords: drug resistance; epi-drugs; epigenetics; epithelial–mesenchymal transition; liquid biopsy; pancreatic ductal adenocarcinoma.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the writing of the manuscript.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7311973/bin/ijms-21-04091-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7311973/bin/ijms-21-04091-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7311973/bin/ijms-21-04091-g003.gif)
Similar articles
-
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.BMC Cancer. 2021 May 29;21(1):632. doi: 10.1186/s12885-021-08388-1. BMC Cancer. 2021. PMID: 34049503 Free PMC article.
-
TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.Gastroenterology. 2021 Aug;161(2):653-668.e16. doi: 10.1053/j.gastro.2021.04.044. Epub 2021 Apr 27. Gastroenterology. 2021. PMID: 33915173
-
An integrated epigenome and transcriptome analysis identifies PAX2 as a master regulator of drug resistance in high grade pancreatic ductal adenocarcinoma.PLoS One. 2019 Oct 17;14(10):e0223554. doi: 10.1371/journal.pone.0223554. eCollection 2019. PLoS One. 2019. PMID: 31622355 Free PMC article.
-
The promise of epigenomic therapeutics in pancreatic cancer.Epigenomics. 2016 Jun;8(6):831-42. doi: 10.2217/epi-2015-0016. Epub 2016 Jun 23. Epigenomics. 2016. PMID: 27337224 Free PMC article. Review.
-
Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma.J Gastroenterol. 2015 Feb;50(2):140-6. doi: 10.1007/s00535-014-0997-0. Epub 2014 Sep 14. J Gastroenterol. 2015. PMID: 25216997 Review.
Cited by
-
Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.Cancers (Basel). 2024 Apr 20;16(8):1589. doi: 10.3390/cancers16081589. Cancers (Basel). 2024. PMID: 38672671 Free PMC article. Review.
-
Attacking Cancer Progression and Metastasis.Int J Mol Sci. 2023 Apr 26;24(9):7858. doi: 10.3390/ijms24097858. Int J Mol Sci. 2023. PMID: 37175564 Free PMC article.
-
Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.Am J Cancer Res. 2022 Dec 15;12(12):5668-5683. eCollection 2022. Am J Cancer Res. 2022. PMID: 36628279 Free PMC article.
-
A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.Clin Epigenetics. 2022 Dec 3;14(1):166. doi: 10.1186/s13148-022-01367-8. Clin Epigenetics. 2022. PMID: 36463226 Free PMC article. Clinical Trial.
-
Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells.Pharmaceuticals (Basel). 2022 Jul 2;15(7):824. doi: 10.3390/ph15070824. Pharmaceuticals (Basel). 2022. PMID: 35890123 Free PMC article.
References
-
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. - PubMed
-
- Siegel R.L., Miller K.D. Jemal ACancer statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. - PubMed
-
- Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. - PubMed
-
- Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356–387. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical